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Endogenously formed prostacyclin (PGI
2
) and synthetic PGI
2
analogues have recently been shown to regulate cell survival in
various cell lines. To elucidate the significance of PGI
2
in human breast cancer, we performed immunohistochemistry to analyze
expression of prostacyclin-synthase (PGIS) in 248 human breast cancer specimens obtained from surgical pathology files. We
examined patients’ 10-year survival retrospectively by sending a questionnaire to their general practitioners and performed
univariate analysis to determine whether PGIS expression correlated with patient survival. Lastly, the effects of PGI
2
and its
analogues on cell death were examined in a human breast cancer cell line (MCF-7) and a human T-cell leukemia cell line (CCRF-
CEM). PGIS expression was observed in tumor cells in 48.7% of samples and was associated with a statistically significant reduction
in 10-year survival (𝑃 = 0.038; 𝑛 = 193). Transient transfection of PGIS intoMCF-7 cells exposed to sulindac increased cell viability
by 50% and exposure to carbaprostacyclin protected against sulindac sulfone induced apoptosis in CCRF-CEM cells. Expression
of PGIS is correlated with a reduced patient survival and protects against cell death in vitro, suggesting that PGIS is a potential
therapeutic target in breast cancer.
1. Introduction
Epidemiological studies have shown that regular intake of
nonsteroidal anti-inflammatory drugs (NSAIDs) is associ-
ated with a reduced incidence of a range of epithelium-
derived malignancies [1]. NSAIDs inhibit the enzymatic
activity of cyclooxygenase (COX), the enzyme that provides
prostaglandin H
2
(precursor to prostacyclin [PGI
2
]) and is
therefore considered to provide the rate-limiting step during
prostanoid synthesis [2]. Two isoforms exist: the constitutive
COX-1 and the inducibleCOX-2. Specific inhibitors of the lat-
ter (also called coxibs or COX-2 selective NSAIDs) have been
developed because gastrointestinal side-effects of NSAIDs
are thought to result from COX-1 inhibition. As COX-2 is
expressed in the majority of human cancers, including breast
cancer [3, 4], COX-2 selective inhibitors (coxibs) next to
COX-2 unselective ones (conventional NSAID) are tested for
their antitumor activity.
The most significant effects of NSAIDs have been
observed in cancers of the digestive tract, including the colon
[5]. The potential effect of NSAIDs in the chemoprevention
of breast cancer is being investigated; however, current
understanding is less clear than in colon cancer. A study in
rats found a reduced relative risk of breast cancer associated
with the use of coxib celecoxib [6]. Results in women are
conflicting: a cohort study in women, which analyzed the
incidence of breast cancer, did not find a protective effect
linked to the intake of aspirin [7]. A beneficial effect of
NSAIDs on the incidence of breast cancer has however
been demonstrated in recent meta-analyses [8–10]. In vitro,
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incubation ofNSAIDswith human breast cancer cell lines has
been shown to induce apoptosis [11].
In contrast to the extensively studied function of COX-
2 in tumor formation, little information exists on the role
of prostanoid forming enzymes and receptors acting down-
stream of COX. Prostacyclin-synthase (PGIS) has recently
been implicated in the regulation of cell survival and induc-
tion of NSAID-mediated cell death in HT29 colon cancer
cells can be abrogated by the addition of carbaprostacyclin, a
synthetic analogue of PGI
2
[12].When exposed to hypertonic
stress, cell death in rabbit renal cells was significantly reduced
by addition of carbaprostacyclin but not by other prostanoids
[13]. In contrast, overexpression of PGIS, as well as exoge-
nously added carbaprostacyclin, induces apoptosis in human
embryonic kidney cells (HEK293) [14]. Prostacyclin activates
the adenylate cyclase coupling prostacyclin-receptor (IP),
whichmediates the anti-aggrgatory effect of PGI
2
on platelets
as well as its vasodilatory action on smooth muscle cells [15].
However, the effects of PGI
2
on cell survival are independent
of cyclic adenosine monophosphate (cAMP) generation and
thus activation of IP. Mounting evidence suggests that PGI
2
can activate the nuclear transcription factor peroxisome
proliferator activated receptor 𝛽/𝛿 (PPAR 𝛽/𝛿). Various fatty
acids including carbaprostacyclin have been suggested to
activate PPAR 𝛽/𝛿 [16]. Activation of PPAR 𝛽/𝛿-reporter
plasmids by cotransfection of PGIS indicate that, in addition
to carbaprostacyclin, endogenously formed PGI
2
may also be
a ligand for PPAR 𝛽/𝛿 [14, 17]. However, in a more recent
study, endogenous PGI
2
was not confirmed as a PPAR 𝛽/𝛿
agonist [18]. Taken together, previous studies suggest that
PGI
2
can regulate cell survival possibly by activation of PPAR
𝛽/𝛿. Therefore, that PGIS could be a target in tumor biology.
In order to elucidate a potential role of PGIS in breast
cancer, we analyzed the expression of this enzyme in human
breast cancer and retrospectively examined its effect on
patient survival. Furthermore, the effect of overexpressing
PGIS on NSAID-induced cell death was studied in a breast
cancer cell line (MCF-7); and the effect of the synthetic
analogue carbaprostacyclin was tested similarly in a human
T-cell leukemia cell line (CCRF-CEM).
2. Materials and Methods
2.1. Case Selection and Histopathology. Cases of patients
with breast cancer (𝑛 = 248, surgery performed 1986–
1990) were retrieved from the surgical pathology files of
the Robert Bosch Krankenhaus (Stuttgart, Germany) and
followed up with a questionnaire sent to their general prac-
titioner. The drop-out rate was 55 patients (22.1%) without
further selection or bias in the remaining 193 cases. The
mean follow-up time was 67.4 months (median: 55 months
[range: 1–119]). Tumor staging was performed according
to World Health Organization guidelines [19]. All patients
had initially undergone either mastectomy surgery or a
breast-conserving resection of their primary carcinomas. We
discriminated ductal invasive carcinoma (78.2%), lobular
invasive carcinoma (8.8%), and invasive carcinoma speci-
fied otherwise (13.0%). Estrogen and progesterone receptor
expression was analyzed biochemically with charcoal and
dextran using 20 fmol/mg protein as cutoff point [20]. In
addition to reviewing pathology reports, slides of all cases
were reexamined for uniform assignment of grade and stage
and other histopathologic features. Only the invasive tumor
component was considered for evaluation.
2.2. Immunohistochemistry. Sections were cut (3 𝜇m thick-
ness), deparaffinized in xylene, and incubated for 30 minutes





peroxidase activity. Sections were then incubated with rabbit
anti-PGIS polyclonal antibodies, as described previously [21].
Briefly, sections were microwaved in phosphate buffered
saline (PBS) containing 0.1M sodium citrate and primary
antibodies were incubated overnight at room temperature.
Immunolabeling was detected using a biotinylated rabbit
anti-goat antibody followed by visualization with an avidin-
biotin horseradish peroxidase labeling kit (Vectastain ABC
kit) and diaminobenzidine staining. The specificity of the
polyclonal antibodies for PGIS used in this study has been
extensively characterized in our previous study analyzing
routinely formalin fixed human tissue cut in serial sections
where identical staining patterns could be demonstrated for
PGIS immunoreactive protein and mRNA using immuno-
histochemistry and radioactive in situ hybridization (ISH),
respectively [21]. Expression of PGIS immunoreactive protein
in human breast cancer samples was analyzed independently
by two investigators who were blinded to patient data. In
tumor tissues, staining intensity was scored visually as absent
(0), weak (1), moderate (2), or strong (3). The percentage of
PGIS-positive tumor cells was graded as absent (0), 1% to
10 (1), 11% to 50% (2), 51% to 80% (3), and 81% or more
(4). The immunoreactive score (IRS) index was calculated
as the product of the two values [22]. Photomicrographs
were viewed with a Leitz RMB microscope and pictures
were captured with a digital camera (Spot-Cam, Diagnostic
Instruments, Sterling Heights, MI). Color composites were
generated by using Adobe Photoshop v5.0 on a Power
Macintosh.
2.3. Cell Culture. MCF-7 human breast carcinoma cells and
CCRF-cells were obtained from DMSZ (Hannover, Ger-
many). MCF-7 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) tissue culture medium supple-
mented with 10% (v/v) fetal bovine serum (FBS) and strepto-
mycin and penicillin. CCRF-cells were grown in Roswell Park
Memorial Institute (RPMI) medium 10% FBS supplemented




. Tissue culture medium was changed every 48–
72 hours.
2.4. Generation and Functional Characterization of a
Prostacyclin-Synthase Expression Vector. A murine full
length PGIS cDNA was amplified from total neonatal
kidney cDNA using Advantage two-step polymerase chain
reaction (Clontech, CA). The PGIS upstream primer was
5󸀠CTTGTTGCCACCCTGCAGCC 3󸀠, and the downstream
primer was 5󸀠CAGGAAGTCAGAAGGCCCCA 3󸀠. DNA-
fragments were cloned into pCDNA 3.1 expression vector
(Invitrogen, Nl) to yield pCDNA3.1mPGIS. An enzymatically
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Figure 1: Immunological detection of prostacyclin-synthase. (a) Western blot analysis of MCF-7 cells transfected with control vector (lane
I: pCDNA 3.1), wild-type (lane II: pCDNA3.1mPGIS), and mutant prostacyclin-synthase (lane III; pCDNA3.1 mPGISC441A). As positive
control PGIS from bovine aorta is shown on the left. ((b), (c)) Expression of immunoreactive PGIS in tumor cells of a ductal carcinoma
showing moderate (b) or intense labeling (c). Slides were photographed at 63x magnification.
inactive mutant of mPGIS (PGIS C441A) was prepared by
site directed mutagenesis (QuikChange, Stratagene, CA)
according to Hatae and coworkers [23]. Oligonucleotide
primers used to prepare the mutants were 5󸀠-AGG GCA
CAA CCA GAG CCT GGG GAA GAG TTA TGC C-3󸀠
and 5󸀠-GGC ATA ACT CTT CCC CAG GCA CTG GTT
GTG CCC T-3󸀠. Expression of wild-type and mutant PGIS
was analyzed by Western blot analysis using the same rabbit
polyclonal antibodies as for the immunohistochemical
analysis as described previously [24]. Briefly, 20𝜇g of
total cell lysates was harvested 48 hours after transfection,
separated on 10% SDS-PAGE, blotted onto nitrocellulose,
and probed with the rabbit polyclonal anti-PGIS antibodies
(diluted 1 : 500). Enzymatic activity of wild-type PGIS
protein was shown by detection of 6-keto-prostaglandin
F1𝛼 (6-keto-PGF
1𝛼
), the stable metabolite of PGI
2
, by
gas-chromatography/mass spectrometry (GC/MS) in
supernatants from transfected cells, as described previously
[25]. Cotransfection for 48 hours of a COX-2 expression
vector (pCDNA3.1COX-2, kindly provided by Dr. Guan
et al. [26], with pCDNA3.1mPGIS (wild-type PGIS)) into
MCF-7 cells resulted in abundant generation of 6-keto-
PGF
1𝛼
(1.48 ± 0.286 ng/mL of supernatant). No significant
generation of 6-keto-PGF
1𝛼
was observed in MCF-7 cells
coexpressing pCDNA3.1COX-2 with either pCDNA3.1 or




2.5. Transfection of cDNA and Experimental Design. All
plasmid-mediated transfections were performed on 40–
60% confluent cells using Polyfect (Qiagen, Germany).
pCDNA3.1mPGIS and pCDNA3.1COX-2 (2𝜇g each) were
transfected into 6-well dishes. Cells were then transferred to
DMEM medium supplemented with 0.5% (v/v) FBS for 24
hours and exposed to 150 𝜇M sulindac and sulindac sulfone
for additional 24 hours. Cell viabilitywas assessed using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay.
The effect of the stable PGI
2
analogue carbaprostacyclin
on cell viability was analyzed in CCRF-CEM cells exposed to
sulindac sulfone. Cells were grown in RPMI supplemented
with 10% (v/v) FBS and gentamycin. CCRF-CEM cells were
coincubated for 48 hours with sulindac sulfone (100 and
300 𝜇M) and either vehicle, increasing concentrations of
carbaprostacyclin (0.01–1 𝜇M), or the membrane permeable
cAMP analogue dibutyryl-cAMP (dbcAMP, 0.001–10mM).
Apoptotic cell death was analyzed by measuring caspase-3
activity as assessed by cleavage of Ac-DEVD-AMC fluoro-
genic substrate (Pharmingen, CA).
2.6. Statistical Methods. Patient data assessments were con-
ducted using SPSS (SPSS Software GmbH, Munich, Ger-
many). Survival curves were established according to the
Kaplan-Meier method, and comparisons between survival
curves were performed with the log-rank test. Overall sur-
vival was calculated from the date of surgery to death or to
the date of the last patient contact. Disease-free survival was
measured from the date of surgery until the time of relapse,
cancer-related death, or last contact. Patients who died from
unrelated causes were considered censored by the time of
their death. To define a cutoff point for PGIS expression, the
minimal 𝑃 value approach was applied. The IRS ≥3 was used
for all further analyses. Multivariate analyses were performed
using Cox regression analysis in amodel with T, N,M, G, and
ER and PR status. Association between PGIS expression and
other parameters such as age, tumor size, nodal status, and
hormonal status was assessed by the test.
Cell culture experiments were analyzed with Student’s 𝑡-
test.
3. Results
3.1. Expression of Prostacyclin-Synthase in MCF-7 Cells. To
confirm expression of wild-type and mutant PGIS pro-
tein, Western blot analysis was performed using MCF-7
cell lysates (20𝜇g per lane). In Figure 1(a), a band could
not be detected in cells transfected with the control vec-
tor pCDNA 3.1 (lane I). Bands of approximately 52 kD
corresponding to the molecular weight of PGIS could be
detected in cells transfected with both the PGIS wild-type
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Table 1: Statistics on patients’ clinical data, classical prognostic factors, and PGIS expression (𝑛 = 193).
Parameter 𝑁(193)
PGIS expression
𝑃IRS: 0–2 % IRS: 3–12 %
Patients (𝑁) Patients (𝑁)
Median age, years 54
Age </>median 83/110 0.127∗
<56 years 83 66 79.5 17 20.5% >0.05∗∗
>56 years 110 84 76.4 54 23.6%
Menopausal status
Pre/post/? 56 37/100/56 0.715∗
Premenopausal 37 30 81.1 7 18.9% >0.05∗∗
Postmenopausal 100 81 81.0 19 19.0%
Tumor size
T1/T2/T3/T4/? 4 29/102/45/8/9 0.0068∗
<2 cm 45 39 86.7 6 13.3% >0.05∗∗
>2 cm 144 109 75.7 35 24.3%
Nodal status
N0/N1/N2/N3/? 3 80/92/13/5/3 <0.0001∗
N0 node negative 80 63 78.8 17 21.3% >0.05∗∗
N1–N3 node positive 110 85 77.3 25 22.7%
Grading
G1/G2/G3/? 4 8/122/59/4 0.0402∗
G1 & G2 130 108 83.1 22 16.9% >0.05∗∗
G3 59 39 66.1 20 33.9%
ER/PR
++//+−&−+//−−//? 96/30/57/10 0.230∗
Pos/pos 96 78 81.2 18 18.8% >0.05∗∗
Pos/neg or neg/pos 30 20 66.6 10 33.3%
Neg/neg 57 43 75.4 14 24.6%
PGIS = prostacyclinsynthase; IRS = immunoreactive score; IRS 0–2 = low PGIS expression; IRS 3–12 = high PGIS expression;𝑁 = number; cm = centimeter;
ER = estrogen receptor; PR = progesterone receptor; pos = positive; neg = negative.
∗
𝑃 value for overall survival (log-rank test).
∗∗P value for expression of PGIS (𝜒2 test).
vector pCDNA3.1mPGIS (lane II) and the mutant PGIS
vector pCDNA3.1 mPGISC441A (lane III). Purified PGIS
frombovine aorta endothelial cell (left lane) served as positive
control.
3.2. Expression of Prostacyclin-Synthase in Breast Cancer
Tissue. Expression of PGIS immunoreactive (ir) protein was
examined in tumor samples from 248 patients with breast
cancer obtained at diagnosis of primary breast cancer disease.
Patient age was 26–86 years; median (±SD) age was 56.49
± 12.11 years. PGIS-immunoreactivity in tumor cells was
observed in 48.7% of samples and was generally weak in
tumor cells. In PGIS-positive tumor cells, cytoplasm and per-
inuclear staining was observed consistent with the expression
of PGIS in the endoplasmic reticulum and the perinuclear
envelope [27]. Expression of PGIS ir-protein in tumor cells
differed in both staining intensity and percentage of positive
tumor cells (Figures 1(b) and 1(c)). PGIS-immunoreactivity
was also observed in various cell samples known to express
this enzyme (fibroblasts: 68%; inflammatory cells: 62.2%; and
vessels 61.7%; data not shown).
3.3. Univariate Analysis. Kaplan-Meier survival curves were
created from the data of 193 patients with complete infor-
mation (see Table 1) to evaluate the prognostic value of
established parameters for overall survival. As expected, the
classical prognostic factors, that is, histology grade, tumor
size, and nodal status, were all significantly associated with
overall survival, whereas age, steroid receptor status, and
menopausal age were not (Table 1). To evaluate a possible
relationship between PGIS expression and disease outcome,
different IRS subgroups were initially defined and Kaplan-
Meier analysis was performed for overall survival. In these
analyses, it became apparent that subgroups with higher
PGIS expression levels had shorter mean survival times
than subgroups with lower expression (data not shown).
This suggested the use of a single cutoff value to simplify
further analyses. To select a value, the minimal 𝑃 value
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Table 2: Kaplan-Meier overall survival analysis for different
immunoreactive scores.
Cutoff (IRS) Number Overall survival prognosis
Log-rank 𝑃 Corrected 𝑃∗
≥1 99/94 5.56 0.0184
≥2 129/64 4.37 0.0377
≥3 150/43 8.37 0.0038
≥4 161/32 6.35 0.0117
≥5 177/16 4.50 0.0338






















IRS: 0–2 (n = 43)
IRS: 3–12 (n = 150)
∗P = 0.038, ∗Bonferroni correction
Figure 2: Relationship between PGIS expression and overall sur-
vival of 193 patients.TheKaplan-Meier survival curves shown are for
subgroups with either low (IRS2) or high (IRS ≥ 3) PGIS expression
among all patients under study.
approach was used, and cutoffs from IRS 1 to 5 were
compared by Kaplan-Meier analysis. The statistical results,
with and without application of the Bonferroni correction
for multiple statistical testing, are listed in Table 2. The most
discriminative value (IRS ≥ 3) was used for further subgroup
analyses andmultivariate Cox regression analysis. At 10 years
following their diagnosis, 64.6% of patients with low PGIS
expression (IRS < 3) were still alive compared with 36.4% in
the group with high PGIS expression (IRS ≥ 3, Figure 2).
3.4. Multivariate Analysis. On multivariate Cox analysis,
the following factors were tested: tumor size, nodal status,
tumor grading, and PGIS expression (cutoff IRS ≥ 3). In this
model, PGIS expression did not prove to be an independent
prognostic factor.
3.5. Overexpression of PGIS in MCF-7 Cells. The role of PGIS
in the protection against NSAID-induced cell death was
examined in human MCF-7 breast cancer cells. In vehicle-
treated (0.1% DMSO) cells viability was not affected by
transfection with wild-type or mutant PGIS vector (com-
pared to control vector, data not shown). Upon exposure
to sulindac (150 𝜇M) for 24 hours, the viability of cells
transfected with control vector and cells transfected with
mutant PGIS was significantly reduced compared withMCF-
7 cells transfected with wild-type PGIS as assessed by the
MTT assay (mock: 0.153 ± 0.19 and PGISC441A: 0.2065 ±
0.038 compared with wild-type PGIS: 0.312 ± 0.048 opti-
cal density 540 nm/690 nm). In contrast to mock- and
pCDNA3.1PGISC441A-transfected cells, overexpression of
wild-type PGIS also increased cell viability in MCF-7 cells
exposed to 150𝜇M sulindac sulfone compared with, albeit to
a lesser extent than with, sulindac (data not shown).
3.6. Effect of Carbaprostacyclin on Cell Viability in CCRF-
Cells. Exposure of CCRF-CEM cells to 100 and 300 𝜇M
sulindac sulfone induced apoptotic cell death in a dose-
dependent manner as analyzed by measurement of caspase-
3 activity (Figure 3(b)). Coincubation of CCRF-CEM cells
with sulindac sulfone and increasing concentrations of car-
baprostacyclin (0.01–1𝜇M) resulted in a decrease of apoptotic
cells by about 50% at either sulindac sulfone concentration
and by carbaprostacyclin 1𝜇M. Thus, treatment with the
synthetic PGI
2
analogue carbaprostacyclin protected against
NSAID-induced apoptosis. Cells were coincubated with
sulindac sulfone and the membrane permeable cAMP ana-
logue dibutyryl-cAMP (dbcAMP) to rule out involvement
of the classical prostacyclin-receptor IP in protection against
apoptotic cell death via elevation of intracellular cAMP. Cell
viability was not affected upon treatment with dbcAMP
suggesting a mode of action independent of IP modulation
(Figure 3(c)).
4. Discussion
To address directly the potential role of PGIS in cell survival,
we analyzed the effects of PGIS-overexpression in a human
breast cancer cell line MCF-7 and of carbaprostacyclin
treatment in a human immature T-cell line CCRF-CEM
cells. MCF-7 cells overexpressing PGIS showed a significant
increase in cell viability when challenged with sulindac and
sulindac sulfone. Given that sulindac inhibits prostaglandin-
production, and thus PGI
2
formation, we assume that PGI
2
generated during the first 24 hours after transfection and
prior to the addition of sulindac rendered the cells resistant
to the adverse effects of sulindac (sulfone).
Apoptotic cell death of sulindac sulfone treated CCRF-
CEM cells exposed to increasing concentrations of car-
baprostacyclin was also significantly reduced. To exclude
an activation of the classical IP pathway, CCRF-CEM cells
were treated with a stable cell permeable cAMP analogue
(dbcAMP). The lack of effect of this agent argues against a
role of the IP-receptor in the protection against apoptosis.
To the best of our knowledge this is the first study to
investigate the expression of PGIS in primary human breast
cancer. Data currently available are conflicting. One investi-
gation found no PGIS expression in human lung carcinoma
[28], whereas another described a significant reduction of
PGIS protein expression in non-small cell lung cancers [29].
However, no correlation with overall patient survival was
observed. A more recent study used the same antibody (anti-
PGIS) to investigate expression in head and neck squamous






































































Figure 3: Effects of overexpression of PGIS and carbaprostacyclin on cell survival. (a) MCF-7 cells were transiently cotransfected with
pCDNA3.1COX-2, together with control vector pCDNA3.1, pCDNA3.1mPGIS, and pCDNA3.1mPGISC441A. Cell viability upon exposure
to 150𝜇M sulindac for 24 hours was examined by the MTT assay as compared to vehicle-treated controls (0.1% DMSO). ((b), (c))
Carbaprostacyclin-mediated protection from sulindac sulfone-induced apoptosis. CCRF-CEM cells were treated with 0, 100, and 300𝜇M
sulindac sulfone in the presence of (b) 0.01–1 𝜇M carbaprostacyclin or (c) 0.001–10mM dbcAMP. 24 hours posttreatment caspase-3 activity
was measured by cleavage of fluorogenic substrate Ac-DEVD-AMC.
cell carcinoma [30]. Lower PGIS levels were observed in
tumor samples than in nontumoral mucosa. Patients who
expressed high levels of PGIS in head and neck squamous cell
carcinomahad a higher 5-year survival rate than the lowPGIS
expressing group.
Our present study using an ISH-validated polyclonal anti-
body [21] on mamma CA also showed weak immunoreactiv-
ity in tumors; however, our striking results from retrospective
analysis revealed that expression of PGIS is associated with a
reduction of patient survival. Although statistical significance
was not achieved, the data indicated that patients with a
high IRS had a worse prognosis than patients with a low
IRS. Given the paucity of data addressing the expression and
roles of PGIS and its putative receptor PPAR 𝛽/𝛿 in human
breast cancer a variety of mechanisms can be postulated that
link PGIS expression with a reduction in patient survival.
Expression of PGIS in human breast cancer cells might
increase their viability in vivo resulting in a less favorable
prognosis than for patients who lack PGIS expression in
their cancerous cells. This is supported by data that showed
that the PPAR 𝛽/𝛿 ligand, cPGI, protects HT29 colon cancer
cells against cell death in vitro [12]. Likewise, cPGI has been
shown to rescue renal medullary interstitial cells from cell
death [13]. Finally, activation of PPAR 𝛽/𝛿 protected cultured
murine keratinocytes against cell death [31]. Importantly, the
contention that PGI
2
promotes survival of breast cancer cells
is compatible with the data from several meta-analyses that
demonstrated the chemopreventive effect of NSAIDs on the
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formation of breast cancer in women [8–10]. Inhibition of
PGI
2
formation by NSAIDs would neutralize the stimulatory
effect of PGI
2
in malignant cells, leading to a reduced
incidence of breast cancer.
Alternatively, PGI
2
might actually reduce cell viability as
shown by a study in which endogenously expressed PGI
2
promoted apoptosis in human embryonic kidney cells and
Caco-2 colon cancer cells [14]. This might indicate that
administration of NSAIDs to patients expressing PGIS might
actually be disadvantageous. This notion is not supported by
epidemiological data, although patient survival has not been
stratified in these patients in terms of PGIS expression.These
apparently contradictory actions of PGI
2
on cell survival may
indicate that its effects are highly dependent on the specific
cellular environment.
Despite the fact that the effects of cPGI and PGIS on
cell survival are clearly divergent, there is agreement that
these effects are not dependent on cAMP generation (and
thus activation of IP) but are possibly mediated by PPAR
𝛽/𝛿 [14, 17, 31–33]. In contrast to PPAR 𝛾 the potential
roles of PPAR 𝛽/𝛿 have yet to be studied in mammary
cancer cells. Two studies addressed the role of PPAR 𝛽/𝛿
in colon cancer, one demonstrated that xenografts of null
cells (PPAR 𝛽/𝛿−/− cells) derived from the human colon
cancer cell line HCT 117 exhibited a significant reduction
in tumor formation compared with wild-type HCT 117 cells
(PPAR 𝛽/𝛿+/+ cells) [34]. However, the essential role of PPAR
𝛽/𝛿 for intestinal tumor formation could not be confirmed
in another study using PPAR 𝛽/𝛿 knockout mice; polyp
size, but not polyp number, was reduced in PPAR 𝛽/𝛿-null
mice compared with wild-type mice [35]. More recently,
we published data showing impaired tumor-angiogenesis in
PPAR 𝛽/𝛿-null mice [36].
Little information exists on the specific role of PGI
2
in





, in breast cancer tissue
are associated with a more aggressive phenotype [37]. In
rats, inhibition of thromboxane-synthase by imidazole led to
enhanced cancer multiplicity in an N-methyl-N-nitrosourea
induced breast cancer model. In contrast, administration of
tranylcypromine which inhibits PGIS has been shown to
reduce cancer multiplicity, indicating that inhibition of this
enzyme, but not thromboxane-synthase, might be useful in
the chemoprevention of breast cancer [38].
5. Conclusions
We have shown that expression of PGIS in human breast
cancer is a negative prognostic factor.Overexpression of PGIS
increases cell viability in MCF-7 cells exposed to sulindac
and sulindac sulfone and carbaprostacyclin protects against
sulindac induced apoptosis in CCRF-CEM cells. The appar-
ent discrepancy to the inverse correlation of PGIS expression
and survival in other carcinomas (e.g., head and neck tumors)
could not only be explained by hormonal biases. More and
larger epidemiological studies in different tumors are needed
to analyze the importance of PGIS expression as an indepen-
dent prognostic factor. The products and molecular targets
of PGIS and their implication in mammary tumor formation
need to be further elucidated to investigate whether certain
subgroups of breast cancer patients show different survival
rates in relation to PGIS expression.
Abbreviations






HEK293: Human embryonic kidney cells
IP: Adenylate cyclase coupling
prostacyclin-receptor
cAMP: Cyclic adenosine monophosphate
PPAR 𝛽/𝛿: Peroxisome proliferator activated receptor
𝛽/𝛿
MCF-7: Human breast cancer cell line
CCRF-CEM: Human T-cell leukemia cell line
PBS: Phosphate buffered saline
ISH: In situ hybridization
IRS: Immunoreactive score
DMEM: Dulbecco’s modified Eagle’s medium
FBS: Fetal bovine serum
RPMI: Roswell Park Memorial Institute
6-Keto-PGF
1𝛼
: 6-Keto prostaglandin F1𝛼








The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This study was supported by grants from Stiftung P. E.
Kempkes (Marburg, Germany) toMartin Ko¨mhoff (19-2001).
The authors thank Dr. H. Schweer for GC/MS analysis of
prostanoids and Dr. Youfei Guan for provision of a rabbit
COX-2 expression vector.
References
[1] M. J. Thun, E. J. Jacobs, and C. Patrono, “The role of aspirin in
cancer prevention,”Nature Reviews Clinical Oncology, vol. 9, no.
5, pp. 259–267, 2012.
[2] W. L. Smith, “Prostanoid biosynthesis and mechanisms of
action,” The American Journal of Physiology: Renal Fluid and
Electrolyte Physiology, vol. 263, no. 2, pp. F181–F191, 1992.
[3] M. Komhoff, Y. Guan, H. W. Shappell et al., “Enhanced expres-
sion of cyclooxygenase-2 in high grade human transitional cell
bladder carcinomas,” The American Journal of Pathology, vol.
157, no. 1, pp. 29–35, 2000.
8 Mediators of Inflammation
[4] R. A. Soslow, A. J. Dannenberg, D. Rush et al., “COX-2
is expressed in human pulmonary, colonic, and mammary
tumors,” Cancer, vol. 89, no. 12, pp. 2637–2645, 2000.
[5] M. J. Thun, M. M. Namboodiri, E. E. Calle, W. D. Flanders, and
C. W. Heath Jr., “Aspirin use and risk of fatal cancer,” Cancer
Research, vol. 53, no. 6, pp. 1322–1327, 1993.
[6] R. E. Harris, G. A. Alshafie, H. Abou-Issa, and K. Seibert,
“Chemoprevention of breast cancer in rats by celecoxib, a
cyclooxygenase 2 inhibitor,” Cancer Research, vol. 60, no. 8, pp.
2101–2103, 2000.
[7] K. M. Egan, M. J. Stampfer, E. Giovannucci, B. A. Rosner, and
G. A. Colditz, “Prospective study of regular aspirin use and the
risk of breast cancer,” Journal of the National Cancer Institute,
vol. 88, no. 14, pp. 988–993, 1996.
[8] S. A. Khuder and A. B. Mutgi, “Breast cancer and NSAID use: a
meta-analysis,” British Journal of Cancer, vol. 84, no. 9, pp. 1188–
1192, 2001.
[9] B. Takkouche, C. Regueira-Me´ndez, and M. Etminan, “Breast
cancer and use of nonsteroidal anti-inflammatory drugs: a
meta-analysis,” Journal of the National Cancer Institute, vol. 100,
no. 20, pp. 1439–1447, 2008.
[10] Y.-S. Zhao, S. Zhu, X.-W. Li et al., “Association betweenNSAIDs
use and breast cancer risk: a systematic review and meta-
analysis,” Breast Cancer Research and Treatment, vol. 117, no. 1,
pp. 141–150, 2009.
[11] E. K.-H. Han, N. Arber, H. Yamamoto et al., “Effects of
sulindac and its metabolites on growth and apoptosis in human
mammary epithelial and breast carcinoma cell lines,” Breast
Cancer Research and Treatment, vol. 48, no. 3, pp. 195–203, 1998.
[12] T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler,
“PPARdelta is an APC-regulated target of nonsteroidal anti-
inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999.
[13] C.-M. Hao, R. Redha, J. Morrow, and M. D. Breyer, “Peroxi-
some proliferator-activated receptor 𝛿 activation promotes cell
survival following hypertonic stress,” The Journal of Biological
Chemistry, vol. 277, no. 24, pp. 21341–21345, 2002.
[14] T.Hatae,M.Wada, C. Yokoyama,M. Shimonishi, andT. Tanabe,
“Prostacyclin-dependent apoptosis mediated by PPAR𝛿,” The
Journal of Biological Chemistry, vol. 276, no. 49, pp. 46260–
46267, 2001.
[15] S. Narumiya, Y. Sugimoto, and F. Ushikubi, “Prostanoid
receptors: structures, properties, and functions,” Physiological
Reviews, vol. 79, no. 4, pp. 1193–1226, 1999.
[16] B.M. Forman, J. Chen, and R.M. Evans, “Hypolipidemic drugs,
polyunsaturated fatty acids, and eicosanoids are ligands for per-
oxisome proliferator-activated receptors𝛼 and 𝛿,”Proceedings of
the National Academy of Sciences of the United States of America,
vol. 94, no. 9, pp. 4312–4317, 1997.
[17] Y. Barak, D. Liao, W. He et al., “Effects of peroxisome
proliferator-activated receptor 𝛿 on placentation, adiposity,
and colorectal cancer,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 99, no. 1, pp. 303–
308, 2002.
[18] T. Fauti, S. Mu¨ller-Bru¨sselbach, M. Kreutzer et al., “Induction
of PPAR𝛽 and prostacyclin (PGI
2
) synthesis by Raf signaling:
failure of PGI
2
to activate PPAR𝛽,” The FEBS Journal, vol. 273,
no. 1, pp. 170–179, 2006.
[19] J. G. Azzopardi, O. F. Chepick, andW.H.Hartmann, “Theworld
Health Organization histological typing of breast tumors—
second edition,” American Journal of Clinical Pathology, vol. 78,
no. 6, pp. 806–816, 1982.
[20] P. Fritz, T. E. Mu¨rdter, M. Eichelbaum, I. Siegle, M. Weissert,
and U. M. Zanger, “Microsomal epoxide hydrolase expression
as a predictor of tamoxifen response in primary breast cancer:
a retrospective exploratory study with long-term follow-up,”
Journal of Clinical Oncology, vol. 19, no. 1, pp. 3–9, 2001.
[21] I. Siegle, T. Klein, M.-H. Zou, P. Fritz, and M. Ko¨mhoff, “Dis-
tribution and cellular localization of prostacyclin synthase in
human brain,”The Journal of Histochemistry and Cytochemistry,
vol. 48, no. 5, pp. 631–641, 2000.
[22] W. Remmele and H. E. Stegner, “Recommendation for uniform
definition of an immunoreactive score (IRS) for immunohisto-
chemical estrogen receptor detection (ER-ICA) in breast cancer
tissue,” Pathologe, vol. 8, no. 3, pp. 138–140, 1987.
[23] T.Hatae, S. Hara, C. Yokoyama et al., “Site-directedmutagenesis
of human prostacyclin synthase: alteration of Cys441 of the
Cys-pocket, and Glu347 and Arg350 of the EXXR motif,” FEBS
Letters, vol. 389, no. 3, pp. 268–272, 1996.
[24] T. Klein, G. Klaus, and M. Ko¨mhoff, “Prostacyclin synthase:
upregulation during renal development and in glomerular
disease as well as its constitutive expression in cultured human
mesangial cells,”Mediators of Inflammation, vol. 2015, Article ID
654151, 9 pages, 2015.
[25] T. Klein, K. Neuhaus, F. Reutter, and R. M. Nu¨sing, “Gener-
ation of 8-epi-prostaglandin F(2alpha) in isolated rat kidney
glomeruli by a radical-independentmechanism,”British Journal
of Pharmacology, vol. 133, no. 5, pp. 643–650, 2001.
[26] Y. Guan, M. Chang, W. Cho et al., “Cloning, expression,
and regulation of rabbit cyclooxygenase-2 in renal medullary
interstitial cells,” The American Journal of Physiology, vol. 273,
no. 1, pp. F18–F26, 1997.
[27] K. K. Wu and J.-Y. Liou, “Cellular and molecular biology of
prostacyclin synthase,” Biochemical and Biophysical Research
Communications, vol. 338, no. 1, pp. 45–52, 2005.
[28] L. Ermert, C. Dierkes, and M. Ermert, “Immunohistochemical
expression of cyclooxygenase isoenzymes and downstream
enzymes in human lung tumors,” Clinical Cancer Research, vol.
9, no. 5, pp. 1604–1610, 2003.
[29] M.-C. Cathcart, S. G. Gray, A.-M. Baird et al., “Prostacyclin
synthase expression and epigenetic regulation in nonsmall cell
lung cancer,” Cancer, vol. 117, no. 22, pp. 5121–5132, 2011.
[30] M.Camacho, Z. Pin˜eiro, S. Alcolea et al., “Prostacyclin-synthase
expression in head and neck carcinoma patients and its prog-
nostic value in the response to radiotherapy,” The Journal of
Pathology, vol. 235, no. 1, pp. 125–135, 2015.
[31] N. S. Tan, L. Michalik, N. Noy et al., “Critical roles of PPAR-
beta/delta in keratinocyte response to inflammation,” Genes &
Development, vol. 15, no. 24, pp. 3263–3277, 2001.
[32] H. Lim, R. A. Gupta, W.-G. Ma et al., “Cyclo-oxygenase-
2-derived prostacyclin mediates embryo implantation in the
mouse via PPAR𝛿,” Genes & Development, vol. 13, no. 12, pp.
1561–1574, 1999.
[33] B. H. Park, B. Vogelstein, andK.W. Kinzler, “Genetic disruption
of PPAR𝛿 decreases the tumorigenicity of human colon cancer
cells,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 98, no. 5, pp. 2598–2603, 2001.
[34] H. E. Marin, M. A. Peraza, A. N. Billin et al., “Ligand activa-
tion of peroxisome proliferator-activated receptor beta inhibits
colon carcinogenesis,” Cancer Research, vol. 66, no. 8, pp. 4394–
4401, 2006.
[35] J. M. Peters, P. Yao, and F. J. Gonzalez, “Targeting peroxi-
some proliferator-activated receptor-𝛽/𝛿 (PPAR𝛽/𝛿) for cancer
Mediators of Inflammation 9
chemoprevention,” Current Pharmacology Reports, vol. 1, no. 2,
pp. 121–128, 2015.
[36] S. Mu¨ller-Bru¨sselbach, M. Ko¨mhoff, M. Rieck et al., “Deregu-
lation of tumor angiogenesis and blockade of tumor growth in
PPARbeta-deficient mice,” The EMBO Journal, vol. 26, no. 15,
pp. 3686–3698, 2007.
[37] G. M. Laekeman, I. B. Vergote, G. M. Keersmaekers et al.,
“Prostacyclin and thromboxane in benign andmalignant breast
tumours,” British Journal of Cancer, vol. 54, no. 3, pp. 431–437,
1986.
[38] D. L. McCormick, A. M. Spicer, and J. L. Hollister, “Differential
effects of tranylcypromine and imidazole onmammary carcino-
genesis in rats fed low and high fat diets,” Cancer Research, vol.
49, no. 12, pp. 3168–3172, 1989.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
